Ulrich Keilholz
Distinguished in WT1-Related Wilms Tumor Syndromes

Ulrich Keilholz

Berlin, BE, DE 
Distinguished in WT1-Related Wilms Tumor Syndromes
Berlin, BE, DE 
OverviewLocationsClinical Research

Overview

Ulrich Keilholz practices in Berlin, Germany. Mr. Keilholz is rated as a Distinguished expert by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Metastatic Uveal Melanoma, Uveal Melanoma, Salpingo-Oophorectomy, and Laryngectomy.

His clinical research consists of co-authoring 205 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of WT1-Related Wilms Tumor Syndromes.

Gender
Male

Locations

Berlin, BE 10115, Germany
Other Locations
Heidelberg, BW, Germany
Dresden, SN, Germany
Mitte, BE, Germany
Homburg, SL 66421, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

TPExtreme: Randomized, Controlled Trial of Platinum-Cetuximab Combined Either With Docetaxel (TPEx) or With 5FU (Extreme) in Patients With Recurrent/Metastatic Squamous Cell Cancer of the Head and Neck
TPExtreme: Randomized, Controlled Trial of Platinum-Cetuximab Combined Either With Docetaxel (TPEx) or With 5FU (Extreme) in Patients With Recurrent/Metastatic Squamous Cell Cancer of the Head and Neck
Enrollment Status: Completed
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drugs: Cisplatin, 5-Fluorouracile, Docetaxel, Cetuximab, Granulocyte Colony-Stimulating Factor (G-CSF)
Study Phase: Phase 2
Randomized Phase II Study of Two Different Regimens of TPF Induction Chemotherapy Regimen Followed by Radiation Therapy Plus Cetuximab (TPF-CET-HART) vs. HART and Cis-platinum, 5-FU (PF-HART) in Patients With Locally Advanced Unresectable Squamous Cell Carcinomas of the Head and Neck
Randomized Phase II Study of Two Different Regimens of TPF Induction Chemotherapy Regimen Followed by Radiation Therapy Plus Cetuximab (TPF-CET-HART) vs. HART and Cis-platinum, 5-FU (PF-HART) in Patients With Locally Advanced Unresectable Squamous Cell Carcinomas of the Head and Neck
Enrollment Status: Completed
Publish Date: January 31, 2019
Intervention Type: Drug, Radiation
Study Phase: Phase 2
View 1 Less Clinical Trial

205 Total Publications

Integrating MALDI-MSI-Based Spatial Proteomics and Machine Learning to Predict Chemoradiotherapy Outcomes in Head and Neck Cancer.
Integrating MALDI-MSI-Based Spatial Proteomics and Machine Learning to Predict Chemoradiotherapy Outcomes in Head and Neck Cancer.
Journal: International journal of molecular sciences
Published: July 21, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Keilholz's expertise for a condition
ConditionClose
View All 27 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile